diagnost tool
htg molecular stress newer push novel
breast lung assay content reiter buy
pleas host newer htg ceo john lubniewski cfo shaun mcmean
annual canaccord genuiti growth confer last week boston key
takeaway htg make bigger push develop launch novel diagnost test
launch breast lung cancer htg get credit stock price
strong y/i growth base ruo profil busi htg taken
advers lump convert cdx yet yet activ
global pharma program reiter buy rate trim pt
would inclin rais htg hit one pharma collabor
edgeseq breast total lung htg develop novel breast lung assay
size across peopl us eu target launch earli
like ghdx oncotypedx htg look better inform treatment plan improv
patient outcom improv identif sub-group new therapi
bay area expans mark push dx last octob htg hire dr maureen cronin
cso laura beggrow presid diagnost formerli vice-president sale market
ghdx share expertis breast cancer dx earli april htg launch dx
develop center san carlo ca initi develop breast
panel look improv upon pioneer oncotypedx breast test ghdx
least expens rna-seq invest think investor abl invest
micro-cap believ htg least expens way precis medicin
pure-play focus rapidli grow rna-seq space htg share trade
revenu estim though remind investor htg activ global
pharma program grow base profil busi
beat rev y/i beat street
htg core product revenu y/i beat off-set
research revenu y/i due lower develop activ
second pharma develop program pdp recal collabor revenu
lumpi htg drove growth pharma pdp revenu lp
match estim htg hold cash balanc sheet
guid reflect view lower pharma collabor rev htg
trim high end revenue guid y/i
expect htg deliv growth target ruo profil y/i
partial off-set lumpy/low pharma pdp collabor revenu year
pdp updat mid-jun htg notifi one pharma develop
partner would use custom-built htg assay cdx regulatori
submiss fda disappoint decis limit singl trial
diseas indic htg continu develop custom assay use trial
repres addit indic htg indic program pdp
riskier activ pdp program given origin pharma trial fail
pharma co tri reviv trial use cdx htg continu
engag biopharma custom involv pdp lack visibl
time final outcom
price close busi august
htg global diagnost compani decentr
rna molecular profil proprietari
platform edgeseq pursu multipl ngs-
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
price target trim htg price target
roll forward multipl revenu estim discount
back year discount rate dilut share outstand prior
pt use multipl revenu estim discount back year
discount rate would inclin rais pt htg hit one
pharma collabor find anoth sourc partnership revenu payment
third-parti collabor acceler growth ruo profil busi and/or
stabil balanc sheet present hold cash end
model primarili conservat around lumpi pdp busi lower
revenu estim y/i vs htgm lower guid
y/i lower revenu y/i model
valuat present exclud opportun compani may realiz beyond
think like includ companion diagnost novel diagnost
time fast-grow rna-seq space given believ estim
achiev conserv
billion pipelin htg current global activ project biopharma
pipelin last quarter htg look exit activ
project htg perform thorough review probability-weight valuat
pipelin size billion valu spread across wide rang
cancer exclud non-oncolog applic ie autoimmun diseas htg
indic call two top five biopharma compani
in-depth studi htg technolog platform htg much
bullish forward-look growth trajectori veri/o lab tucson arizona
amend april htg amend ivd test develop agreement
develop commerci rna dna profil test
use ilmn miseqdx sequenc oncolog diagnost updat agreement
may extend autoimmun diseas cardiovascular diseas fibrosi
diseas htg plan enter auto-immun market launch gene
express liquid biopsi auto-immun panel later base understand
exist assay compat sequenc platform htg taken
step make cell origin lung fusion ruo assay compat
ion torrent platform htg believ make assay sequenc agnost
drive interest europ estim instal base clinic
sequenc near
amend agreement extend beyond oncolog htg april amend
ivd test develop suppli agreement involv
develop commerci nuclease-protection-bas rna dna
profil test use ilmn miseqdx sequenc oncolog diagnost
updat agreement extend beyond oncolog includ diagnost test
autoimmun disord diseas cardiovascular disord diseas
fibrosi disord diseas htg plan enter auto-immun market launch
liquid biopsi auto-immun panel later research-us
new ceo announc earlier year tj johnson serv htg ceo
year move role chairman john lubniewski formerli htg presid
cbo promot ceo role known john sinc htg ipo believ
highli capabl compet execut deepli familiar htg growth
initi custom base like tj john ex-ventana medic execut
edgeseq reveal htg roll edgeseq reveal new softwar product use
analyz htg edgeseq precis immuno-oncolog panel data htg assert
product help enabl applic like monitor immunotherapi respons
biomark immunophenotyp applic use determin diseas
buy unchang target price august
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
